세계의 규제 컨설팅 아웃소싱 서비스 시장 규모, 점유율 및 동향 분석 보고서 : 카테고리별, 적응증별, 최종 용도별, 기업 규모별, 지역별, 부문별 예측(2024-2030년)

Regulatory Consulting Outsourcing Services Market Size, Share & Trends Analysis Report By Category (Pharmaceuticals, Medical Devices), By Company Size, By Indication, By End-use, By Region, And Segment Forecasts, 2024 - 2030

US $ 5,950 ￦ 8,272,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 9,662,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,443,000

Printable PDF & Excel (Enterprise License)

보고서 구매 기업 및 그 자회사, 관계사가 사용할 수 있는 라이선스이며, PDF 및 엑셀 텍스트 등의 복사 및 붙여넣기, 인쇄가 가능합니다.

한글목차

규제 컨설팅 아웃소싱 서비스 시장 성장 및 동향 :

Grand View Research, Inc.의 최신 보고서에 따르면, 규제 컨설팅 아웃소싱 서비스 세계 시장 규모는 2030년까지 8.36%의 연평균 복합 성장률(CAGR)로 19억 달러에 달할 것으로 예상됩니다.

임상시험과 관련된 비용을 억제하기 위한 아웃소싱 업체들 증가와 엄격한 규제 준수가 이 시장의 주요 촉진요인으로 작용하고 있습니다. 의료 규정 준수는 복잡하고 끊임없이 진화하고 있습니다. 아웃소싱을 통해 기업은 사내 팀을 유지하지 않고도 규제, 규정 준수 및 품질 보증 전문 지식을 활용할 수 있습니다.

규제 컨설팅 회사는 전 세계에 임상시험 규제 서비스를 제공하고 중앙 집중식 데이터 관리와 다양한 제출 서류를 동시에 관리할 수 있는 능력을 결합하여 신속한 시험 시작을 돕습니다. 예를 들어, 2023년 6월 FDA는 임상시험 현대화를 위한 추가 조치를 발표했으며, FDA는 제안된 가이드라인과 다양한 임상시험 유형 및 데이터 리소스에 대한 적용 가능성에 대한 의견을 요청했습니다. 규제 프레임워크가 진화하고 임상시험 프로세스가 현대화됨에 따라, 의료 기업들은 컴플라이언스 요건을 준수하는 데 있어 더욱 복잡한 문제에 직면하게 될 것입니다. 이러한 복잡성으로 인해 변화하는 규제를 준수하기 위한 규제 컨설팅 서비스에 대한 수요가 증가할 것으로 예상됩니다.

바이오제약 및 의료기기 기업의 세계화는 주요 시장 성장 촉진요인 중 하나입니다. 바이오제약 및 의료기기 기업들은 새로운 시장을 개척하기 위해 전 세계적으로 사업을 확장하고 있습니다. 중국, 인도, 브라질 등 신흥국은 의료비 증가, 선진 의료에 대한 수요 증가, 규제 환경 개선 등으로 인해 큰 성장 기회를 제공합니다. 규제 컨설팅 회사는 특정 시장에 맞는 규제 경로, 제품 등록 및 컴플라이언스 전략에 대한 전략적 자문을 제공함으로써 시장 진입을 촉진하는 데 있어 매우 중요합니다.

규제 컨설팅 아웃소싱 서비스 시장 보고서 하이라이트

• 카테고리별로는 제약 부문이 2023년 가장 큰 점유율을 차지했습니다. 이는 제약 산업의 규제 상황이 복잡하고 진화하고 있기 때문입니다.
• 종양은 2023년 상당한 시장 점유율을 차지했습니다. 이는 암의 높은 유병률과 안전하고 효과적인 치료 옵션에 대한 필요성이 증가하고 있기 때문입니다.
• 규제 컨설팅 아웃소싱 서비스에서 제약기업이 큰 비중을 차지하고 있으며, 2023년 매출 점유율은 40.24%를 넘어섰습니다. 여러 오리지널 의약품의 특허가 만료됨에 따라 제네릭 의약품 신청 및 관련 서비스 규제 서비스가 활성화되어 시장 성장을 가속할 것으로 예상됩니다.
• 중견기업 부문은 2023년 큰 수익 점유율을 차지했습니다. 이러한 업계의 중견기업은 자원과 기술 부족에 자주 직면하기 때문에 일반적으로 프로젝트 단위로 공급업체와 계약하고 아웃소싱 계약을 통해 신청 및 신고 관리를 컨설턴트에게 위탁하는 것이 일반적입니다.
• 2023년 규제 컨설팅 아웃소싱 서비스 시장에서 북미가 30% 이상의 가장 큰 점유율을 차지했습니다. 규제 컴플라이언스에 정통하고 효과적인 솔루션을 제공한 경험이 있는 컨설팅 회사가 존재하기 때문에 규제 지원을 원하는 기업이 이 지역 시장 성장을 주도하고 있습니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 규제 컨설팅 아웃소싱 서비스 시장 변수, 동향, 범위

• 시장 계통 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 규제 컨설팅 아웃소싱 서비스 시장 분석 툴
  • 업계 분석 - Porter의 Five Forces 분석
  • PESTEL 분석

제4장 규제 컨설팅 아웃소싱 서비스 시장 : 카테고리 추정·동향 분석

• 부문 대시보드
• 규제 컨설팅 아웃소싱 서비스 시장 : 카테고리 변동 분석
• 세계의 규제 컨설팅 아웃소싱 서비스 시장 규모·동향 분석, 카테고리별, 2018년-2030년
• 의약품
• 생물학적 제제
• 의료기기

제5장 규제 컨설팅 아웃소싱 서비스 시장 : 적응증 추정·동향 분석

• 부문 대시보드
• 규제 컨설팅 아웃소싱 서비스 시장 : 적응증 변동 분석
• 세계의 규제 컨설팅 아웃소싱 서비스 시장 규모·동향 분석, 적응증별, 2018년-2030년
• 종양
• 신경
• 심장병
• 면역
• 기타

제6장 규제 컨설팅 아웃소싱 서비스 시장 : 최종 용도 추정·동향 분석

• 부문 대시보드
• 규제 컨설팅 아웃소싱 서비스 시장 : 최종 용도 변동 분석, 2022년·2030년
• 세계의 규제 컨설팅 아웃소싱 서비스 시장 규모·동향 분석, 최종 용도별, 2018년-2030년
• 바이오테크놀러지 기업
• 제약 기업
• 의료기기 기업

제7장 규제 컨설팅 아웃소싱 서비스 시장 : 기업 규모 추정·동향 분석

• 부문 대시보드
• 규제 컨설팅 아웃소싱 서비스 시장 : 기업 규모 변동 분석, 2022년·2030년
• 세계의 규제 컨설팅 아웃소싱 서비스 시장 규모·동향 분석, 기업 규모별, 2018-2030년
• 소
• 중
• 대

제8장 규제 컨설팅 아웃소싱 서비스 : 지역 추정·동향 분석

• 규제 컨설팅 아웃소싱 서비스 : 지역 변동 분석, 2022년·2030년
• 북미
  • 미국
  • 캐나다
• 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 덴마크
  • 스웨덴
  • 노르웨이
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 호주
  • 태국
  • 한국
• 라틴아메리카
  • 브라질
  • 멕시코
  • 아르헨티나
• 중동 및 아프리카
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 쿠웨이트

제9장 경쟁 구도

• 기업 분류
• 기업의 시장 점유율 분석, 2023년
• 전략 매핑
• 기업 개요/상장기업
  • Parexel International Corporation
  • ICON plc
  • IQVIA
  • Syneos Health
  • Navigant Consulting, Inc.
  • Premier Research
  • Weinberg Group
  • ProPharma
  • PharmaLex GmbH
  • LabCorp

LSH

영문 목차

영문목차

Regulatory Consulting Outsourcing Services Market Growth & Trends:

The global regulatory consulting outsourcing services market size is expected to reach USD 1.90 billion by 2030, registering at a CAGR of 8.36%, according to a new report by Grand View Research, Inc. Rising number of outsourcing players to curb costs associated with clinical trials and stringent regulatory compliance are key drivers for this market. Healthcare regulatory compliance is complex and constantly evolving. Outsourcing allows organizations to access specialized expertise in regulatory affairs, compliance, and quality assurance without having to maintain an in-house team.

The regulatory consulting firms provide clinical trial regulatory services globally, assisting them through faster trial start-ups by combining centralized data administration with the capacity to manage various regulatory submissions simultaneously. For instance, in June 2023, FDA Announces Further Measures to Modernize Clinical Trials. The Agency Seeks Input on the Proposed Guidelines and Their Applicability Across a Range of Trial Varieties and Data Resources. As regulatory frameworks evolve and clinical trial processes modernize, healthcare companies encounter greater complexity in navigating compliance requirements. This complexity is expected to drive demand for regulatory consultancy services to ensure adherence to changing regulations.

Globalization of biopharmaceuticals and medical device companies is likely to be one of the major market drivers. Biopharmaceutical and medical device companies expanded their operations globally to tap into new markets. Emerging economies like China, India, Brazil, and others offer significant growth opportunities due to rising healthcare expenditures, increasing demand for advanced medical treatments, and improving regulatory environments. Regulatory consulting firms are crucial in facilitating market entry by providing strategic advice on regulatory pathways, product registration, and compliance strategies tailored to specific markets.

Regulatory Consulting Outsourcing Services Market Report Highlights:

• By Category, the drugs segment held the largest share in 2023. This is attributed to the complex and evolving regulatory landscape of the pharmaceutical industry
• Oncology held a substantial market share in 2023. This can be attributed to the high prevalence of cancer, prompting a need for safe and effective treatment options
• Pharmaceutical companies held a major share in regulatory consulting outsourcing services with a revenue share of over 40.24% in 2023. The patent expiry of several branded drugs is anticipated to boost regulatory services for generic applications and related services, thereby facilitating market growth
• The mid-size companies segment holds a major revenue share in 2023. Mid-size companies in such industries frequently encounter shortages in resources and technology, leading them to engage with suppliers on a project-by-project basis and commonly delegate application and submission management to consultants through outsourcing arrangements
• North America held the largest share of over 30% in the regulatory consulting outsourcing services market in 2023. The presence of established consulting firms with deep expertise in regulatory compliance and a strong track record of delivering effective solutions attracts businesses seeking regulatory support to drive regional market growth

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Market Definitions
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
• 1.5. Details of primary research
  • 1.5.1. Data for primary interviews in North America
  • 1.5.2. Data for primary interviews in Europe
  • 1.5.3. Data for primary interviews in Asia Pacific
  • 1.5.4. Data for primary interviews in Latin America
  • 1.5.5. Data for Primary interviews in MEA
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.1.1. Approach 1: Commodity flow approach
  • 1.7.2. Volume price analysis (Model 2)
    • 1.7.2.1. Approach 2: Volume price analysis
• 1.8. Research Scope and Assumptions
  • 1.8.1. List of Secondary Sources
  • 1.8.2. List of Primary Sources
  • 1.8.3. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Regulatory Consulting Outsourcing Services Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Increasing Regulatory Complexity
    • 3.2.1.2. Technological Advancements
    • 3.2.1.3. Rising Cost of Compliance
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Data Security and Confidentiality Concerns
• 3.3. Regulatory Consulting Outsourcing Services Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Bargaining power of the suppliers
    • 3.3.1.2. Bargaining power of the buyers
    • 3.3.1.3. Threats of substitution
    • 3.3.1.4. Threats from new entrants
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Economic and Social Landscape
    • 3.3.2.3. Technological landscape

Chapter 4. Regulatory Consulting Outsourcing Services Market: Category Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Regulatory Consulting Outsourcing Services Market: Category Movement Analysis
• 4.3. Global Regulatory Consulting Outsourcing Services Market Size & Trend Analysis, by Category, 2018 to 2030 (USD Million)
• 4.4. Drugs
  • 4.4.1. Drugs Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.5. Biologics
  • 4.5.1. Biologics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.6. Medical Devices
  • 4.6.1. Medical Devices Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Regulatory Consulting Outsourcing Services Market: Indication Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Regulatory Consulting Outsourcing Services Market: Indication Movement Analysis
• 5.3. Global Regulatory Consulting Outsourcing Services Market Size & Trend Analysis, by Indication, 2018 to 2030 (USD Million)
• 5.4. Oncology
  • 5.4.1. Oncology Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.5. Neurology
  • 5.5.1. Neurology Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.6. Cardiology
  • 5.6.1. Cardiology Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.7. Immunology
  • 5.7.1. Immunology Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.8. Others
  • 5.8.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Regulatory Consulting Outsourcing Services Market: End Use Estimates & Trend Analysis

• 6.1. Segment Dashboard
• 6.2. Regulatory Consulting Outsourcing Services Market: End Use Movement Analysis, 2022 & 2030 (USD Million)
• 6.3. Global Regulatory Consulting Outsourcing Services Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
• 6.4. Biotechnology Companies
  • 6.4.1. Biotechnology Companies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.5. Pharmaceutical Companies
  • 6.5.1. Pharmaceutical Companies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.6. Medical Device Companies
  • 6.6.1. Medical Device Companies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Regulatory Consulting Outsourcing Services Market: Company Size Estimates & Trend Analysis

• 7.1. Segment Dashboard
• 7.2. Regulatory Consulting Outsourcing Services Market: Company Size Movement Analysis, 2022 & 2030 (USD Million)
• 7.3. Global Regulatory Consulting Outsourcing Services Market Size & Trend Analysis, by Company Size, 2018 to 2030 (USD Million)
• 7.4. Small
  • 7.4.1. Small Companies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.5. Medium
  • 7.5.1. Medium Companies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.6. Large
  • 7.6.1. Large Companies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Regulatory Consulting Outsourcing Services: Regional Estimates & Trend Analysis, by Services, by Area, by Demographic

• 8.1. Regulatory Consulting Outsourcing Services: Regional Movement Analysis, 2022 & 2030
• 8.2. North America
  • 8.2.1. North America Regulatory Consulting Outsourcing Services Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.2.2. U.S.
    • 8.2.2.1. Key Country Dynamics
    • 8.2.2.2. Competitive Scenario
    • 8.2.2.3. Prevalence Insights
    • 8.2.2.4. Regulatory Framework
    • 8.2.2.5. Reimbursement Structure
    • 8.2.2.6. U.S. Regulatory Consulting Outsourcing Services Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.2.3. Canada
    • 8.2.3.1. Key Country Dynamics
    • 8.2.3.2. Competitive Scenario
    • 8.2.3.3. Prevalence Insights
    • 8.2.3.4. Regulatory Framework
    • 8.2.3.5. Reimbursement Structure
    • 8.2.3.6. Canada Regulatory Consulting Outsourcing Services Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.3. Europe
  • 8.3.1. Europe Regulatory Consulting Outsourcing Services Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.3.2. UK
    • 8.3.2.1. Key Country Dynamics
    • 8.3.2.2. Competitive Scenario
    • 8.3.2.3. Prevalence Insights
    • 8.3.2.4. Regulatory Framework
    • 8.3.2.5. Reimbursement Structure
    • 8.3.2.6. UK Regulatory Consulting Outsourcing Services Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.3.3. Germany
    • 8.3.3.1. Key Country Dynamics
    • 8.3.3.2. Competitive Scenario
    • 8.3.3.3. Prevalence Insights
    • 8.3.3.4. Regulatory Framework
    • 8.3.3.5. Reimbursement Structure
    • 8.3.3.6. Germany Regulatory Consulting Outsourcing Services Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.3.4. France
    • 8.3.4.1. Key Country Dynamics
    • 8.3.4.2. Competitive Scenario
    • 8.3.4.3. Prevalence Insights
    • 8.3.4.4. Regulatory Framework
    • 8.3.4.5. Reimbursement Structure
    • 8.3.4.6. France Regulatory Consulting Outsourcing Services Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.3.5. Italy
    • 8.3.5.1. Key Country Dynamics
    • 8.3.5.2. Competitive Scenario
    • 8.3.5.3. Prevalence Insights
    • 8.3.5.4. Regulatory Framework
    • 8.3.5.5. Reimbursement Structure
    • 8.3.5.6. Italy Regulatory Consulting Outsourcing Services Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.3.6. Spain
    • 8.3.6.1. Key Country Dynamics
    • 8.3.6.2. Competitive Scenario
    • 8.3.6.3. Prevalence Insights
    • 8.3.6.4. Regulatory Framework
    • 8.3.6.5. Reimbursement Structure
    • 8.3.6.6. Spain Regulatory Consulting Outsourcing Services Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.3.7. Denmark
    • 8.3.7.1. Key Country Dynamics
    • 8.3.7.2. Competitive Scenario
    • 8.3.7.3. Prevalence Insights
    • 8.3.7.4. Regulatory Framework
    • 8.3.7.5. Reimbursement Structure
    • 8.3.7.6. Denmark Regulatory Consulting Outsourcing Services Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.3.8. Sweden
    • 8.3.8.1. Key Country Dynamics
    • 8.3.8.2. Competitive Scenario
    • 8.3.8.3. Prevalence Insights
    • 8.3.8.4. Regulatory Framework
    • 8.3.8.5. Reimbursement Structure
    • 8.3.8.6. Sweden Regulatory Consulting Outsourcing Services Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.3.9. Norway
    • 8.3.9.1. Key Country Dynamics
    • 8.3.9.2. Competitive Scenario
    • 8.3.9.3. Prevalence Insights
    • 8.3.9.4. Regulatory Framework
    • 8.3.9.5. Reimbursement Structure
    • 8.3.9.6. Norway Regulatory Consulting Outsourcing Services Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.4. Asia Pacific
  • 8.4.1. Asia Pacific Regulatory Consulting Outsourcing Services Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.4.2. Japan
    • 8.4.2.1. Key Country Dynamics
    • 8.4.2.2. Competitive Scenario
    • 8.4.2.3. Prevalence Insights
    • 8.4.2.4. Regulatory Framework
    • 8.4.2.5. Reimbursement Structure
    • 8.4.2.6. Japan Regulatory Consulting Outsourcing Services Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.4.3. China
    • 8.4.3.1. Key Country Dynamics
    • 8.4.3.2. Competitive Scenario
    • 8.4.3.3. Prevalence Insights
    • 8.4.3.4. Regulatory Framework
    • 8.4.3.5. Reimbursement Structure
    • 8.4.3.6. China Regulatory Consulting Outsourcing Services Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.4.4. India
    • 8.4.4.1. Key Country Dynamics
    • 8.4.4.2. Competitive Scenario
    • 8.4.4.3. Prevalence Insights
    • 8.4.4.4. Regulatory Framework
    • 8.4.4.5. Reimbursement Structure
    • 8.4.4.6. India Regulatory Consulting Outsourcing Services Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.4.5. Australia
    • 8.4.5.1. Key Country Dynamics
    • 8.4.5.2. Competitive Scenario
    • 8.4.5.3. Prevalence Insights
    • 8.4.5.4. Regulatory Framework
    • 8.4.5.5. Reimbursement Structure
    • 8.4.5.6. Australia Regulatory Consulting Outsourcing Services Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.4.6. Thailand
    • 8.4.6.1. Key Country Dynamics
    • 8.4.6.2. Competitive Scenario
    • 8.4.6.3. Prevalence Insights
    • 8.4.6.4. Regulatory Framework
    • 8.4.6.5. Reimbursement Structure
    • 8.4.6.6. Thailand Regulatory Consulting Outsourcing Services Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.4.7. South Korea
    • 8.4.7.1. Key Country Dynamics
    • 8.4.7.2. Competitive Scenario
    • 8.4.7.3. Prevalence Insights
    • 8.4.7.4. Regulatory Framework
    • 8.4.7.5. Reimbursement Structure
    • 8.4.7.6. South Korea Regulatory Consulting Outsourcing Services Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.5. Latin America
  • 8.5.1. Latin America Regulatory Consulting Outsourcing Services Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.2. Brazil
    • 8.5.2.1. Key Country Dynamics
    • 8.5.2.2. Competitive Scenario
    • 8.5.2.3. Prevalence Insights
    • 8.5.2.4. Regulatory Framework
    • 8.5.2.5. Reimbursement Structure
    • 8.5.2.6. Brazil Regulatory Consulting Outsourcing Services Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.3. Mexico
    • 8.5.3.1. Key Country Dynamics
    • 8.5.3.2. Competitive Scenario
    • 8.5.3.3. Prevalence Insights
    • 8.5.3.4. Regulatory Framework
    • 8.5.3.5. Reimbursement Structure
    • 8.5.3.6. Mexico Regulatory Consulting Outsourcing Services Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.4. Argentina
    • 8.5.4.1. Key Country Dynamics
    • 8.5.4.2. Competitive Scenario
    • 8.5.4.3. Prevalence Insights
    • 8.5.4.4. Regulatory Framework
    • 8.5.4.5. Reimbursement Structure
    • 8.5.4.6. Argentina Regulatory Consulting Outsourcing Services Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.6. Middle East & Africa
  • 8.6.1. Middle East & Africa Regulatory Consulting Outsourcing Services Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6.2. South Africa
    • 8.6.2.1. Key Country Dynamics
    • 8.6.2.2. Competitive Scenario
    • 8.6.2.3. Prevalence Insights
    • 8.6.2.4. Regulatory Framework
    • 8.6.2.5. Reimbursement Structure
    • 8.6.2.6. South Africa Regulatory Consulting Outsourcing Services Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6.3. Saudi Arabia
    • 8.6.3.1. Key Country Dynamics
    • 8.6.3.2. Competitive Scenario
    • 8.6.3.3. Prevalence Insights
    • 8.6.3.4. Regulatory Framework
    • 8.6.3.5. Reimbursement Structure
    • 8.6.3.6. Saudi Arabia Regulatory Consulting Outsourcing Services Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6.4. UAE
    • 8.6.4.1. Key Country Dynamics
    • 8.6.4.2. Competitive Scenario
    • 8.6.4.3. Prevalence Insights
    • 8.6.4.4. Regulatory Framework
    • 8.6.4.5. Reimbursement Structure
    • 8.6.4.6. UAE Regulatory Consulting Outsourcing Services Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6.5. Kuwait
    • 8.6.5.1. Key Country Dynamics
    • 8.6.5.2. Competitive Scenario
    • 8.6.5.3. Prevalence Insights
    • 8.6.5.4. Regulatory Framework
    • 8.6.5.5. Reimbursement Structure
    • 8.6.5.6. Kuwait Regulatory Consulting Outsourcing Services Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Company Categorization
• 9.2. Company Market Share Analysis, 2023
• 9.3. Strategy Mapping
• 9.4. Company Profiles/Listing
  • 9.4.1. Parexel International Corporation
    • 9.4.1.1. Overview
    • 9.4.1.2. Financial Performance
    • 9.4.1.3. Product Benchmarking
    • 9.4.1.4. Strategic Initiatives
  • 9.4.2. ICON plc
    • 9.4.2.1. Overview
    • 9.4.2.2. Financial Performance
    • 9.4.2.3. Product Benchmarking
    • 9.4.2.4. Strategic Initiatives
  • 9.4.3. IQVIA
    • 9.4.3.1. Overview
    • 9.4.3.2. Financial Performance
    • 9.4.3.3. Product Benchmarking
    • 9.4.3.4. Strategic Initiatives
  • 9.4.4. Syneos Health
    • 9.4.4.1. Overview
    • 9.4.4.2. Financial Performance
    • 9.4.4.3. Product Benchmarking
    • 9.4.4.4. Strategic Initiatives
  • 9.4.5. Navigant Consulting, Inc.
    • 9.4.5.1. Overview
    • 9.4.5.2. Financial Performance
    • 9.4.5.3. Product Benchmarking
    • 9.4.5.4. Strategic Initiatives
  • 9.4.6. Premier Research
    • 9.4.6.1. Overview
    • 9.4.6.2. Financial Performance
    • 9.4.6.3. Product Benchmarking
    • 9.4.6.4. Strategic Initiatives
  • 9.4.7. Weinberg Group
    • 9.4.7.1. Overview
    • 9.4.7.2. Financial Performance
    • 9.4.7.3. Product Benchmarking
    • 9.4.7.4. Strategic Initiatives
  • 9.4.8. ProPharma
    • 9.4.8.1. Overview
    • 9.4.8.2. Financial Performance
    • 9.4.8.3. Product Benchmarking
    • 9.4.8.4. Strategic Initiatives
  • 9.4.9. PharmaLex GmbH
    • 9.4.9.1. Overview
    • 9.4.9.2. Financial Performance
    • 9.4.9.3. Product Benchmarking
    • 9.4.9.4. Strategic Initiatives
  • 9.4.10. LabCorp
    • 9.4.10.1. Overview
    • 9.4.10.2. Financial Performance
    • 9.4.10.3. Product Benchmarking
    • 9.4.10.4. Strategic Initiatives

관련자료